ClinicalTrials.gg
Active, not recruitingNCT05203627Updated Nov 5, 2026

Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

An interventional study of Best Practice and Questionnaire Administration in Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2020, registered Dec 2021).
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Stomach Neoplasms by City of Hope Medical Center — 7 open to participants now, 9 under way, none of them phase 3. Stomach Neoplasms · City of Hope Medical Center.

Enrollment
3rd of 14
53 · median 19
Started
2020
with 1 other
No phase
6 of 21
1 open now
Registered
13th of 21
by date

Among the 21 studies in Stomach Neoplasms by City of Hope Medical Center, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 with no phase, and was the 13th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 21 studies in Stomach Neoplasms by City of Hope Medical Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Stomach Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This clinical trial test whether taking part in a diet support intervention will help with patients nutrition and quality of life after surgery for esophagus or stomach cancer. The information learned by doing this research study may help patients get more information and/or support on eating after esophagus and stomach cancer surgery.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the feasibility, retention, and satisfaction of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention as measured by the percentage of patients who a) agree to participate; b) complete a majority of the intervention (at least 2 sessions); and c) report satisfaction with the intervention (through structured exit interviews).

II. Assess the preliminary efficacy of TIMES for patient reported outcomes for quality of life (QOL), dietary symptoms, and self-management.

III. Assess the preliminary efficacy of TIMES for objective measures of patient nutrition.

OUTLINE: Patients are randomized in to 1 of 2 arms.

ARM I: Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.

ARM II: Patients receive standard nutritional support.

After completion of study, patients are followed up for 6 months.

03

Conditions studied

  • Gastric Carcinoma
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The ability to understand English or Spanish.
  • Undergone curative intent surgery for gastric or gastroesophageal (GE) junction cancer.
  • Began oral intake within the past month.
  • Aged 21 years and older.
  • Able to participate in telehealth sessions.
  • This study will be conducted in patients aged 21 years or older who have undergone curative intent surgery for gastric or GE junction cancer.
  • Age criterion for this trial is based on the National Institute of Health (NIH')s age criteria, which defines an adult as individuals aged 21 years and over. There are no restrictions related to performance status or .
  • All subjects must have the ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Arm I (telehealth session, guidebook)

    Patients receive 4 telehealth sessions over 1 hour each over 4 months. Patients also receive an intervention guidebook.

    Other: Questionnaire Administration · Other: Telemedicine Visit

  • Active comparator
    Arm II (standard nutritional support)

    Patients receive standard nutritional support.

    Other: Best Practice · Other: Questionnaire Administration

Interventions

  • OtherBest Practice

    Receive standard nutritional support

    Also known as: standard of care, standard therapy

  • OtherQuestionnaire Administration

    Ancillary studies

  • OtherTelemedicine Visit

    Receive telehealth sessions

06

What researchers measure

Primary outcomes

  1. Feasibility of the Telehealth Intervention - Percent Participation

    Feasibility of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention will be measured by the percentage of patients who agree to participate.

    Time frame: Up to 6 months

  2. Feasibility of the Telehealth Intervention - Percent Completion

    Feasibility of the Telehealth Intervention for Self-Management of Eating after Gastric Surgery (TIMES) intervention will be measured by the percentage of patients who completes two sessions.

    Time frame: Up to 6 months

  3. Retention of the TIMES intervention

    Measured by the percentage of patients who complete a majority of the intervention (at least 2 sessions).

    Time frame: Up to 6 months

  4. Satisfaction of the TIMES intervention

    Measured by the percentage of patients who report satisfaction with the intervention (through structured exit interviews). Satisfaction and engagement will be assessed through the exit interview via qualitative data, content analysis approach.

    Time frame: Up to 6 months

  5. Patient reported outcomes - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ30):

    EORTC-QLQ30 will be assessed with a 30-item instrument for QOL assessment, with subscales/items for function, global health, general symptoms (fatigue, pain, nausea, and vomiting), and financial toxicity.

    Time frame: Up to 6 months

  6. Patient reported outcomes - EORTC-Oesophago-Gastric Cancer Module

    (EORTC-OG25) will be assessed with a 25-item measure for esophagogastric cancer-specific symptoms and emotional well-being.

    Time frame: Up to 6 months

  7. Patient reported outcomes - Patient Activation Measure (PAM)

    Patient Activation Measure (PAM) will be assessed by using a Guttman-like scale that reflects a patient's level of engagement and empowerment in their healthcare.

    Time frame: Up to 6 months

  8. Patient reported outcomes - General Self-Efficacy Scale

    A General Self-Efficacy Scale developed by Jerusalem and colleagues contains 10 items that assess perceived confidence in self-management. Items are rated on a 4-point Likert scale.

    Time frame: Up to 6 months

  9. Patient reported outcomes - The Post-Gastrectomy Nutrition Questionnaire

    The Post-Gastrectomy Nutrition Questionnaire is a tool developed by the investigators to assess patient knowledge about diet and nutrition after surgery for GE cancer. Each item addresses specific content discussed in the telehealth sessions to assess changes in knowledge. Scoring is based on the number of questions answered correctly.

    Time frame: Up to 6 months

  10. Objective measures of patient nutrition - Weight

    Weight will be recorded at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition. Weight will be measured by kg.

    Time frame: Up to 6 months

  11. Objective measures of patient nutrition - Body Mass Index (BMI)

    Body Mass Index will be calculated and recorded by dividing weight in Kg by height in m\^2 at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition.

    Time frame: Up to 6 months

  12. Objective measures of patient nutrition - Albumin levels

    Serum albumin levels collected as routine follow-up care will be recorded at baseline and 6 months to examine the preliminary efficacy of the intervention on objective measures of patient nutrition. Albumin level will be measured g/dl.

    Time frame: Up to 6 months

  13. Objective measures of patient nutrition - Skeletal mass Index

    Sarcopenia/skeletal muscle mass will be calculated at baseline and 6 months through CT scans performed as part of routine follow-up for gastroesophageal cancer include cross-sectional images at the level of the third lumbar vertebra (L3). The cross-sectional area of skeletal muscle mass in this region has been found in multiple studies to correlate with total body skeletal muscle mass. Skeletal muscle mass will be quantified using well described techniques applying a predefined Hounsfield unit (HU) threshold of -25 to 150 HU for skeletal muscle mass. Muscle boundaries will be corrected manually when necessary to obtain cross-sectional areas (cm2) for skeletal muscle. Skeletal muscle index (SMI, cm2/m2) is defined as the cross-sectional area of muscle at the L3 level normalized for BMI.

    Time frame: Up to 6 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2027, 83 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 83 months is above that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Oct 2026 → Jan 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2021
First posted
Jan 24, 2022
StartActual
Jan 21, 2020
Primary completionEst.
Jan 4, 2027was Oct 2026
CompletionEst.
Feb 4, 2027was Oct 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Jan 4, 2027
Nov 5, 2026
Study completion
Oct 1, 2026→Feb 4, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Oct 1, 2026→Jan 4, 2027
    Study completion Oct 1, 2026→Feb 4, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05203627
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Jan 21, 2020
Primary completion
Jan 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Jae Y Kim
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion